A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

TB4 accelerated wound healing endpoints in a rat model compared with controls.

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

GHK-Cu significantly increased MMP-2 (matrix metalloproteinase-2) protein levels and corresponding mRNA in fibroblast culture media. TIMP-1 and TIMP-2 secretion also rose, indicating balanced matrix remodeling activity. The copper component was essential - GHK peptide alone produced no effect. Authors conclude GHK-Cu acts as both an activator of connective tissue production and a regulator of extracellular matrix remodeling.

Review summarizes reported improvements in some skin measures & broad tissue-remodeling biology; quality & comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.

One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations & endpoints.